Finnish Breast Cancer Group (FBCG)

摘要

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by Finnish Breast Cancer Group (FBCG). Clinical trials include: Comparison of vinorelbine versus docetaxel, and trastuzumab versus no trastuzumab as adjuvant treatments of early breast cancer. FinHer studyRandomized phase III study comparing single-agent docetaxel followed by 5-FU, epirubicin and cyclophosphamide (FEC) to docetaxel plus Xeloda followed by cyclophosphamide, epirubicin and Xeloda (CEX) as adjuvant treatment for early breast cancer. FinXX StudyA multicenter phase III open randomised trial of the efficacy of exercise in the prevention of long-term adverse effects of adjuvant treatments and breast cancer recurrences in women with primary breast cancer. BREX 01-2004 Study